Hong Kong Stock Announcement Nuggets | China Biopharmaceuticals and Boehringer Ingelheim reached a strategic cooperation with a potential total value of 7 billion US dollars
Important matters:
Yasheng Pharmaceutical (06855): A number of clinical developments will be presented at the 2026 American Society of Hematology Annual Meeting (ASH). Among them, APG-5918 received an oral report
Kingsley Biotechnology (01548): Legend announced that it will be exhibited at the American Society of Hematology Annual Meeting
Brain Motion Aurora-B (06681): The first round of the “Brain Star • Healthy Brain Community Tour - National Community Healthy Brain Life Series” theme competition was successfully held to promote a pilot project to promote community brain health prevention and intervention
Funds under Shoucheng Holdings (00697) invest in simple and smart card slots around high-quality physical AI data
Stress Holdings (02663) changed ownership with a discount of about 13.8% and offered a full purchase offer to resume trading on November 5
Maike Pharmaceutical-B (02335) received the first project funding under a major national science and technology project and obtained ethical approval from the MT200605 phase III clinical trial team leader
Hanwang Gold (03788) reports mineral processing metallurgical test results of recent drilling samples in the historic waste pile area of the Rustlers Roost gold deposit
Hehong Service (06093) plans to sell 100% of Guiyang Xinglong Property Management Co., Ltd.'s shares for 115 million yuan
Federal Pharmaceuticals (03933): Application for marketing registration of simeglutide injection accepted
League of Nations Minsheng (01456): League of Nations Futures plans to exchange shares to absorb and merge Minsheng Futures
Shanghai Pharmaceutical (02607): Triprostenil diethanolamine inhalation powder obtained clinical trial approval notice
Ning Meng Film and Television (09857): “Today is the Sun and Rain” is scheduled to be broadcast exclusively on both Hunan TV and Mango TV platforms on November 6
Fosun Pharmaceutical (02196): FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria started a phase III clinical trial in China1
Honghua Group (00196) subsidiary signed a drilling rig sales agreement with a Central Asian customer for a total amount of about US$59 million
China Biopharmaceuticals (01177) and Boehringer Ingelheim reached a strategic cooperation with a potential total value of 7 billion US dollars
Fu Hong Han Lin (02696): Phase 1 clinical trial of HLX109 injection (monoclonal antibody targeting IL1RAP) for the treatment of generalized pustular psoriasis was approved in Australia
China Star Aerospace (06935) November 5 to November 10 stock offering is expected to be listed on November 13
ASMPT (00522) completes strategic program evaluation and retains SMT Solutions Division
Keji Pharmaceutical-B (02171): CT1190B and CT071 abstracts were presented at the 2026 ASH Annual Meeting
Hehuang Pharmaceutical (00013) announced that solepinib (sovleplenib) has been certified as an orphan drug by the FDA for the treatment of autoimmune hemolytic anemia
Balkang Shiyun-B (02592): Top results of the Phase 3 study of CBT-001 for patients with pterygium
Yuanda Pharmaceutical (00512): The international multi-center phase III clinical trial of the innovative global ophthalmology drug CBT-001 for pterygium reached the main clinical end
Operating performance:
Auto Home-S (02518) announced third quarter results, net profit attributable to shareholders of 195 million yuan
Prudential (02378)'s third-quarter new business profit of US$709 million rose 1%
Kerry International (01050) is happy to announce that profit attributable to shareholders is expected to increase by about 100% year-on-year in the medium term
Big Fun Group (00341) is pleased to see profit attributable to shareholders of HK$95.8 million to HK$105 million increase 105% to 125% year-on-year
Manulife Financial-S (00945) announces third quarter results, core profit of 2.1 billion Canadian dollars, up 4% year-on-year